However, due to limited evidence, the safety of recommending intravenous tissue plasminogen activators for patients with acute stroke and CCM remains uncertain.<h4>Methods</h4>Our study identified five patients with acute stroke and CCM treated between 2017 and 2023 across two hospitals. The gene discussed is PLAT; the disease is cerebral cavernous malformation.